A

A

1 A

2 A

35

A

A

A

3 A

20 80%

20 20

/ 20

4 A 47,780,100

30%

5 A 6

6 A 94,800.00

1		82,080.00	74,800.00
2		20,000.00	20,000.00
		102,080.00	**94,800.00**

7 A

8 A

9

2012 37 3

2022 3

3

.....7

.....10

.....10

.....11

.....17

.....20

.....20

.....20

.....20

.....21

.....21

.....21

.....29

.....30

.....31

.....31

.....31

.....32

.....32

.....33

.....33

.....33

.....37

.....37

.....40

.....40

.....44

.....44

.....44

		300436.SZ
		2023 A
		2023 A
		5%
		A
		/ I II III IV

PCT		Patent Cooperation Treaty
IND		Investigational New Drug Application
NDA		New Drug Application

1961

Frost&Sullivan 1000

Fujian Cosunter Pharmaceutical Co., LTD.

159,267,000

1-7

7

16

2001 6 28

300436

350108

0591-38265188

0591-83052199

www.cosunter.com

linxiaohui@cosunter.com

(

) ( )

(

)

74,691,217

46.90%

1

Frost & Sullivan 2020

12,988 2030 20,333

2016 9,328 2020 10,009

2030 12,194 60%

2016-2030

年复合增长率	化学药	生物药	总计
2016-2020	1.8%	7.8%	3.0%
2020-2025E	2.8%	12.2%	5.3%
2025E-2030E	1.6%	9.0%	4.9%



Frost & Sullivan 2016 13,294

2020 14,480 2025 2030 22,873

29,911 2020

7,085 2030 11,438

2016-2030

年复合增长率	化学药	生物药	中药	总计
2016-2020	-0.5%	17.1%	-1.8%	2.2%
2020-2025E	6.6%	18.6%	4.9%	9.6%
2025E-2030E	3.2%	9.8%	2.0%	5.5%



2

2020

2021

3

2019

6

2,000 RNA



https://ourworldindata.org/coronavirus#explore-the-global-situation

Nextstrain

2022 5

BA.4/BA.5

Nextstrain

+

4

HBV

WHO 2019 2.96 82

150

2021

2017

100 7,000

15%

0%-3%

Frost & Sullivan

2030 2030 723.3 2025-2030 35.8%



Frost & Sullivan

1

6

2

A

A

A

A

20 80%

20 20

/ 20

A 6

A 94,800.00

1		82,080.00	74,800.00
2		20,000.00	20,000.00
		102,080.00	**94,800.00**

A

46.90%

A 47,780,100

30%

36.07% ,

1 A

2 A

3 A

4

A

A 94,800.00

1		82,080.00	74,800.00
2		20,000.00	20,000.00
		102,080.00	**94,800.00**

1

82,080.00

74,800.00

GST-HG171 GST-HG141 GST-HG121

GST-HG171 3CL

BA.4 BA.5

GST-HG171

II/III

GST-HG141 GST-HG141 HBV cccDNA GST-HG141

GST-HG141 Ib II II

GST-HG121 HBsAg First-in-class GST-HG121 RNA HBsAg GST-HG121 HBsAg GST-HG121 I

2

1

2019

6 2,000 RNA



https://ourworldindata.org/coronavirus#explore-the-global-situation

Nextstrain

2022 5

BA.4/BA.5

Nextstrain

+

2

HBV

2021

2017

100 7,000

15%

2019

HBsAg HBV DNA

0%-3%

GST-HG121 GST-HG141

3

3

1

2021

2

GST-HG171 3CL

3CL 3CL Mpro

16

RNA

3CL 3CL

3CL

3CL

GST-HG171

I GST-

HG171 GST-

HG171 Nirmatrelvir 2.6-

3.0 5 GST-HG171

PK Nirmatrelvir

GST-HG171 GST-

HG171

GST-HG121 GST-HG141

HBsAg GST-HG121

First-in-class

RNA HBsAg

GST-HG121

HBsAg GST-HG141 HBV

cccDNA

I GST-HG141

3

2015 IPO

PCT

4

20

CEO

George Zhang

20

John Wei-Zhong Mao 25

18 INDs 2 NDAs Foresee

Pharmaceuticals Cytokinetics Idenix Pharmaceuticals

4

82,080.00

74,800.00

5

1

20,000.00

2

1

3,398.81

1,559.75 -1,776.48 -7,772.83

2

	5,321.34	4,747.18	6,898.95	
12,014.95		12.83%	40.39%	

3

A

GST-HG171

2022 9 30 32.68%

1

2

1

2

3

1,258.49	1,652.86	-3,416.40

10%

50%

25%

2

2

2/3

1

2

3

20%

4

2018 -2020 2020-2022

2019 -2021

2012 37 3

2022 3

2023 -2025

10%

2023 -2025

1

2

3

10%

1

80%

2

40%

3

20%

20% 5,000

4

5

2

6

2/3

1

2

3

20%

4

[2013]110

[2014]17

[2015]31

94,800.00

47,780,100

159,267,000 207,047,100

1

1

2 2023 6

3

4 47,780,100
94,800.00

5 2021 2021
-3,488.66 -
4,607.63 2022
2021 2023
2022
50% 50%

6

7 2022

8

9
2022
2022

2

	2022 / 2022 12 31	2023 / 2023 12 31	
	159,267,000.00	159,267,000.00	207,047,100.00
1 2023 2022 50%			
	-34,886,550.27	-52,329,825.41	-52,329,825.41
	-46,076,269.97	-69,114,404.96	-69,114,404.96
/	-0.22	-0.33	-0.29
/	-0.29	-0.43	-0.38
/	-0.22	-0.33	-0.29
/	-0.29	-0.43	-0.38
2 2023 2022			
	-34,886,550.27	-34,886,550.27	-34,886,550.27
	-46,076,269.97	-46,076,269.97	-46,076,269.97
/	-0.22	-0.22	-0.19
/	-0.29	-0.29	-0.25
/	-0.22	-0.22	-0.19
/	-0.29	-0.29	-0.25
3 2023 2022 50%			
	-34,886,550.27	-17,443,275.14	-17,443,275.14
	-46,076,269.97	-23,038,134.99	-23,038,134.99
/	-0.22	-0.11	-0.10
/	-0.29	-0.14	-0.13
/	-0.22	-0.11	-0.10
/	-0.29	-0.14	-0.13

1 9

1

2

GST-HG171 GST-HG141 GST-HG121

3

4

5

2012 37 3

2022 3

/

/

/ /

/

/

/

/

2023 1 6